Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments

OAK RIDGE, TN – September 30, 2025 – Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces significant commercial momentum and clinical validation following the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The company’s successful debut of its newly FDA-cleared, next-generation BVA analyzer signals a new era of data-driven fluid management for a multi-billion-dollar market.

The initial response from clinicians confirmed robust market demand for the new system, driven by its enhanced ease of use, speed, and over 95% accuracy.